Monopar Therapeutics announced its financial results for Q4 and full-year 2025, highlighting progress toward submitting a New Drug Application (NDA) for ALXN1840 in Wilson disease by mid-2026. ALXN1840, a novel treatment targeting copper accumulation in organs, showed promising long-term efficacy and safety data. The company strengthened its leadership and balance sheet in 2025, with $140.4 million in cash to support operations through 2027. Monopar also advanced its radiopharmaceutical programs targeting aggressive cancers, with ongoing Phase 1 trials and regulatory clearances. The NDA submission and potential launch of ALXN1840 mark key upcoming milestones.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
